News

Biovica’s CEO and main shareholder lends shares for redemption of option program

Biovica’s CEO and main shareholder Anders Rylander has, to facilitate the administration of the company’s warrant program 3, lent 127,000 shares to Pareto Securities AB.

January 12, 2021

Biovica’s DiviTum®TKa included in new UK breast cancer study

DiviTum®TKa has been selected to be included in a new prospective study of women with hormone receptor positive metastatic breast cancer. The aim of including DiviTum®TKa in the study is to investigate if this marker can be used for disease monitoring during treatment with a CDK4/6 inhibitor, which in combination with an aromatase inhibitor is considered standard of care for this subgroup of patients.

November 23, 2020

Multicenter study PYTHIA presents positive DiviTum®TKa results

Biovica, active in cancer diagnostics, today announced that positive DiviTum®TKa results from the European multicenter study PYTHIA will be presented at the world´s leading breast cancer conference, SABCS, in early December.

November 20, 2020

CDK 4/6 dosing study supports DiviTum®TKa as an early and effective tool in treatment monitoring and prediction of response

Biovica, active in cancer diagnostics, today announced that positive DiviTum®TKa results from a clinical study at the University of Nebraska Medical Center and Washington University School of Medicine, US, will be presented at the world´s leading breast cancer conference, SABCS. The study supports using DiviTum®TKa to monitor efficacy during treatment and predict response to the CDK 4/6 inhibitor palbociclib.

November 19, 2020

Biovica announces initial results in clinical genomics study of DiviTum®TKa

November 18, 2020 — Biovica, active in cancer diagnostics, today announced that initial results from the PROMISE study (NCT03281902) will be presented at the San Antonio Breast Cancer Symposium (December 8-11, 2020).

November 18, 2020

DiviTum®TKa Monitoring Capabilities Confirmed in SWOG Study

Biovica, active in cancer diagnostics, today announced that new DiviTum®TKa results from a large SWOG Cancer Research Network study further strengthen DiviTum®TKa’s monitoring capabilities within metastatic breast cancer. The study, known as S0226, showed impressive data on progression free survival and overall survival. Furthermore, results support that DiviTum®TKa can predict benefit from metastatic breast cancer therapy. The new results will be presented at the world’s leading breast cancer conference, the San Antonio Breast Cancer Symposium, in December.

November 17, 2020

Biovica’s DiviTum®TKa in four posters at SABCS

Biovica, active in cancer diagnostics, today announced that four abstracts based on studies using the blood test DiviTum®TKa have been accepted as posters at the world’s largest breast cancer symposium, SABCS, in early December.

October 23, 2020

Biovica completes analytical validation as part of FDA application

Biovica, active in cancer diagnostics, today announced that the analytical validation of the blood test DiviTum has been completed. The validation aims to verify technical and precision requirements defined in consultation with the US Food and Drug Administration (FDA). The analytical validation is an important part of the application for US market approval.

June 17, 2020

Biovica’s DiviTum® acknowledged in ASCO educational book

Uppsala, Sweden, May 22, 2020. The ASCO educational book 2020 highlights DiviTum® as a solution to address unmet needs within monitoring treatment effect of CDK4/6 inhibitors.

May 22, 2020

Biovica’s DiviTum® and TK activity acknowledged in highly renowned scientific journals

Uppsala, Sweden, May 11, 2020. The scientific journals British Journal of Cancer, a Nature journal, and Biomarkers in Medicine have published articles on DiviTum® results and TK activity as a biomarker for evaluating efficacy of CDK4/6 inhibitors. The editorials conclude that DiviTum data has the potential to become a standard prognostic biomarker and tool for early recognition of treatment resistance in metastatic breast cancer.

May 11, 2020